A Study to Evaluate the Diagnostic Potential of a Lateral Flow Assay to Detect QSOX1 Peptide in Patients With or At Risk for Pancreatic Cancer
Tab Title Description
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Scottsdale/Phoenix, Arizona: 19-004658
NCT ID: NCT04064034
Sponsor Protocol Number: 19-004658
About this study
The purpose of this study is to evaluate the lateral flow assay (LFA) to be used in conjunction with imaging and existing biomarkers in diagnosed or at-risk-for pancreatic cancer patients.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
- Group 1. Pancreas Cancer (n=20). Adult patients with biopsy-proven adenocarcinoma prior to receiving any therapy such as surgery, radiation or chemotherapy.
- Group 2 (n=20). Patients without pancreas cancer. Adult patients with benign pancreas disorders such as pancreatitis with imaging within 12 months (CT, MRI, EUS) documenting no cancer. Healthy adults with blood specimens in an existing biobank.
- Group 3 (n=20). Patients with pancreatic cystic lesions. Adult patients undergoing clinically indicated EUS-guided FNA biopsy of pancreatic cystic lesions.
- Prior treatment for pancreas cancer.
- Unable or unwilling to give consent.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
|Mayo Clinic Location
Mayo Clinic principal investigator
Douglas Faigel, M.D.
Closed for enrollment
Publications are currently not available